Compare CTNT & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTNT | HCWB |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 3.6M |
| IPO Year | 2023 | 2021 |
| Metric | CTNT | HCWB |
|---|---|---|
| Price | $3.22 | $1.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 32.7M | 751.1K |
| Earning Date | 11-06-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.74 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,288,536.00 | ★ $4,099,750.00 |
| Revenue This Year | $78.50 | $12,215.61 |
| Revenue Next Year | $52.17 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 182.69 | N/A |
| 52 Week Low | $0.03 | $0.86 |
| 52 Week High | $2,120.00 | $25.44 |
| Indicator | CTNT | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 60.01 | 27.80 |
| Support Level | $2.95 | $0.86 |
| Resistance Level | $4.18 | $3.07 |
| Average True Range (ATR) | 0.34 | 0.12 |
| MACD | 0.19 | -0.01 |
| Stochastic Oscillator | 72.83 | 9.93 |
Cheetah Net Supply Chain Service Inc is a provider of logistics and warehousing services, historically in connection with the sale of parallel-import vehicles sourced in the U.S. to be sold in the PRC market, and more recently for the transportation of other goods between the U.S. and the PRC. Parallel-import vehicles in the PRC refer to automobiles purchased directly from overseas markets and imported for sale outside of the brand manufacturer's official distribution networks. The company operates as single report segment. The company operates in the USA and overseas.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.